Objective We have created a three finger peptide able to target specifically the pl90BCR-ABL oncogene. The purpose of this project will be to develop a procedure in which the molecules that can interfere specifically with oncogene activity (ie. anti p190BCR-ABL peptide in our case) is co-introduced to the targeted cells (murine haematopoietic pro-B Ba/F3 cell lines expressing the pl90BCR-ABL oncogene and bone marrow cells derived from pl90BCR-ABL transgenic mice) via such vectors as viruses which encode a selectable cell surface expression marker (truncated human CD5 in our case). The targeted cells expressing the surface marker are completely separated from untargeted cells by sorting techniques for transfer back into the recipient. We hope that this gene therapy based approach will facilitate the development of a novel and curative treatment for Ph l-positive human leukaemias. Fields of science medical and health sciencesmedical biotechnologygenetic engineeringgene therapynatural sciencesbiological sciencesmicrobiologyvirologynatural sciencesbiological sciencesbiochemistrybiomoleculesmedical and health sciencesclinical medicineoncologyleukemia Programme(s) FP4-TMR - Specific research and technological development programme in the field of the training and mobility of researchers, 1994-1998 Topic(s) 0303 - Return grants TL02 - Molecular Biology and Biochemistry Call for proposal Data not available Funding Scheme RGI - Research grants (individual fellowships) Coordinator Consejo Superior de Investigaciones Científicas Address S/n,avenida de campo charro s/n 37007 Salamanca Spain See on map EU contribution No data Participants (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all Not available Spain EU contribution € 0,00 Address See on map Other funding No data
